INTRODUCTION
Even though bipolar disorder is a mental disorder with a course of episodes where patients are suggested to recover between episodes, it has been shown that they do not recover completely during remission 1 and they do not achieve premorbid functioning 2 . Both occupational and social functioning of the patients do not revert to premorbid levels and while their productivity decreases, their well-being is impaired markedly 4 . There are various factors affecting the functionality of patients during remission. Among these, residual or sub-syndromal depressive symptoms are the most studied and suggested to be the cause. It has been demonstrated that residual depressive symptoms have impacts on social, occupational and cognitive functioning [5] [6] [7] . In addition, comorbid conditions such as anxiety disorders, medical conditions or diseases and pharmacological treatment for such conditions may have effects on functioning.
It is widely known that bipolar patients are on intensive drug treatment during the course of their illness 8 . The number and variety of psychotropic drugs are increased during manic episodes 9 and most of the drugs are prescribed for a long time. On the other hand, second-generation antipsychotics have an important role in the treatment of bipolar disorder and they are used either as combination therapy or as an alternative treatment to mood stabilizers in routine daily practice 10 . The impact of drug treatment on the impairment of psychosocial functioning in bipolar patients is not well studied. In a study by Yen et al. 11 , it has been suggested that use of second-generation antipsychotics do not have any effect on quality of life, but there are some differences among the drugs themselves. However, it has been indirectly shown that the number of psychotropic drugs had a negative impact on quality of life of bipolar patients 3 . As a result, it has not been determined, how this effect is caused and how it is related to daily life.
In this study, the aim was to determine the effect of psychotropic drug treatment on psychosocial functioning in bipolar patients during remission.
With this purpose, beside the factors, which have been shown previously to have effects on psychosocial functioning, a model was used which also takes into consideration pharmacological treatment modalities. 
METHOD

Study Sample
The study is carried out with remitted bipolar patients. Inclusion criteria were being older than 18 years, fulfilling the diagnosis bipolar disorder type I or II according to DSM-IV criteria, and having the cognitive ability to comply with study procedure. The diagnostic assessment of the patients was made by the psychiatry specialists who are the authors of the study. Exclusion criteria were having any psychiatric disorder including any alcohol or substance misuse other than bipolar disorder type I or II, and having any neurological or organic diagnosis requiring permanent treatment. Only patients in remission were included to the study. The remission state was confirmed by a 17-item Hamilton Depression Rating Scale (HAM-D) score less than 7 and a Young Mania Rating Scale (YMRS) score less than 4 at the time of the SCID-CV interview. One hundred and forty-seven patients were screened for the study, but only 108 patients, who were in remission were included.
The study was approved by the Local Ethical Committee of Celal Bayar University.
Study Instruments
For assessing mood symptoms, the Young Mania Rating Scale (YMRS) 12 and the 17-item Hamilton Depression Rating Scale (HAM-D) 13 were used.
For assessing the level of psychosocial functioning of the patients, the Functional Assessment Short Test (FAST) was used. The FAST was developed by Rosa et al. 14 and the validation study for Turkish was performed by Aydemir and Uykur 15 . It is a 24-item self-rated scale with 4-point Likert type rating, and it has six domains: autonomy, occupational functioning, cognitive functioning, financial issues, interpersonal relations, and leisure time activities. A higher score means worse functioning. The FAST does not have a cut-off point; and even though it has domains, the total score is used in the analysis.
Statistical Analysis
To evaluate the impact of pharmacological treatment modalities on psychosocial functioning, a stepwise regression model was established. The model was tested with multiple linear regression analyses. The patients were separated into two groups, patients, who were only on mood stabilizers (MS) and patients who were on mood stabilizers combined with a second-generation antipsychotic (MS+SGA), and the model was tested on these two groups. In this model, in addition to the pharmacological treatment modality for every domain of functioning, mood symptoms such as depression and mania, duration of the disease and number of mood episodes were also taken into account. Accordingly, in the first step total scores of the HAM-D and YMRS, in the second step duration of the disease and number of mood episodes and in the third step pharmacological treatment modalities were included in the regression model. Monotherapy versus combination therapy was considered as a dummy variable and combination therapy (MS+SGA) was coded as 1. This model was repeated for every domain of psychosocial functioning in the analysis.
RESULTS
In the study 108 volunteers were included and the mean age was 39.1±11.6 years; female patients were 57.4% (n=62) of the group. Nearly all of the patients (92.6%) were diagnosed as bipolar disorder type I. The duration of the disease was 11.8±8.4 years, and mean number of previous mood episodes was 19 .6±31.0. Demographic and clinical features of the patients are shown in Table 1 . While 38% (n=41) of the patients were on only mood stabilizers, 67 patients (62%) were on mood stabilizers combined w i t h s e c o n d -g e n e r a t i o n a n t i p s y c h o t i c s. Pharmacological drug treatment of the patients is shown in Table 2 .
In the multiple linear regression analysis where a model for each domain of psychosocial functioning was tested, autonomy, interpersonal relations, and leisure time activities were found to be statistically significant ( 
DISCUSSION
In this study, psychosocial functioning of remitted bipolar patients was evaluated and the effect of pharmacological treatment was determined. Like in previous studies 16 , while it has been shown that the effect of depressive symptoms have an impact on psychosocial functioning, it was also demonstrated that in patients with a treatment combining mood stabilizer and second-generation antipsychotic, domains of psychosocial functioning such as autonomy, interpersonal relations and leisure time activities were negatively affected. This study is the first study to assess directly the impact of pharmacological treatment on psychosocial functioning.
It has been previously demonstrated that pharmacological treatment in bipolar disorder, especially second-generation antipsychotics were shown to have negative effect on cognitive functions 17 . On the other hand, especially in schizophrenic patients, it was suggested that second-generation antipsychotics had a better effect on psychosocial functioning and quality of life, compared to classical antipsychotics 18 , but when the severe impairment of schizophrenic patients is taken into consideration, it is not expected that they would achieve their premorbid level of functioning 19 . In a study on lithium treatment in bipolar disorder, it has been suggested that the treatment improved the quality of life of the patients by preventing the recurrence of mood episodes 20 . In studies on psychosocial functioning and quality of life in bipolar disorder, number of psychotropic drugs and adverse effects of pharmacological treatment have been found to affect functioning negatively 3 . In another study based on a classification taking into account global functioning score and occupational status, bipolar patients were classified into two classes regarding their pharmacological treatment as having good or poor functions, and lithium and valproate are found to be statistically significant in the good functioning group 21 . Yen et al. 11 evaluated quality of life in patients with bipolar disorder compared both with patients with schizophrenia and healthy control subjects, and studied the effect of second-generation antipsychotics. Quality of life of bipolar patients was similar to that of patients with schizophrenia and worse than that of healthy control subjects, and it was suggested that pharmacological treatment does not have any effect. In addition, patients who experience adverse events have worse quality of life than patients who have never used psychotropic drugs. As a result, use of second-generation antipsychotics affects quality of life negatively. In this present study, it has been demonstrated that combination therapy has negative effect on the domains of psychosocial functioning such as autonomy, interpersonal relations and leisure time activities
In previous studies, it has been reported that patients with a difficult-to-treat disorder, with more residual symptoms and with a more frequently recurrent course of disease require more drugs in treatment 8 . Since the psychopathology of these patients is already more severe, it is expected that they have poor functioning. On the other hand, in bipolar patients, second-generation antipsychotics cause more adverse effects, and patients have difficulties in adapting to their treatment 22 . It should be considered that adverse effects have a significant effect on functioning and quality of life 3 . As a result, beside residual depressive symptoms, in bipolar patients second-generation antipsychotics also reduce participation in leisure time activities, cause avoidance of interpersonal relations, and reduce initiative by affecting autonomy.
Advantages and limitations of the study
This study is a cross-sectional study and since it does not cover the follow-up period, it may be inadequate to demonstrate longitudinal effects of symptoms and therapies. Thus, longitudinal studies are needed to generalize the results. Since the study is cross-sectional, bipolar patients, who are only on mood stabilizers may have a disease with a more favorable course or less severe episodes when compared with patients who are on mood stabilizers combined with second-generation antipsychotics. Therefore when reading the results of the study, it should be kept in mind that the difference in functioning may be caused by factors other than treatment modalities. The study was carried out in institutions with specialized mood disorder clinics, and at the same time in tertiary health care centers, therefore one should be cautious to generalize the results of this study. The advantages of this study are that is has an adequate sample size and that the subgroups have similar features.
CONCLUSION
Even though bipolar patients achieve remission, they do not return to their premorbid level of psychosocial functioning. Beside residual depressive symptoms, second-generation antipsychotics used in the treatment also have a negative impact. In the long-term follow-up of patients with bipolar disorder, psychotropic drugs should be reviewed, drugs that are not needed anymore should be tapered off, and cost benefit ratio of ongoing psychotropic drugs should be taken into account.
